Inspire Medical Systems (NYSE:INSP – Get Free Report) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.200-1.400 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of $850.0 million-$860.0 million, compared to the consensus revenue estimate of $853.6 million.
Inspire Medical Systems Stock Performance
Shares of Inspire Medical Systems stock opened at $66.39 on Thursday. Inspire Medical Systems has a 52-week low of $38.91 and a 52-week high of $147.03. The firm has a 50-day moving average of $68.80 and a 200-day moving average of $58.51. The stock has a market cap of $1.92 billion, a PE ratio of 30.49, a PEG ratio of 4.58 and a beta of 0.67.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $206.69 million for the quarter, compared to analyst estimates of $204.31 million. Inspire Medical Systems had a return on equity of 7.32% and a net margin of 11.43%. The company’s revenue was down 7.9% on a year-over-year basis. During the same quarter last year, the company earned $0.38 EPS. Equities research analysts predict that Inspire Medical Systems will post 1.27 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
INSP has been the topic of a number of research analyst reports. Zacks Research downgraded Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. Barclays dropped their price objective on Inspire Medical Systems from $65.00 to $62.00 and set an “underweight” rating for the company in a research report on Tuesday. Stifel Nicolaus lifted their target price on Inspire Medical Systems from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, September 11th. Piper Sandler boosted their target price on Inspire Medical Systems from $60.00 to $70.00 and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Weiss Ratings raised shares of Inspire Medical Systems from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $71.24.
Check Out Our Latest Stock Analysis on INSP
Insider Activity at Inspire Medical Systems
In related news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider directly owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.20% of the stock is currently owned by corporate insiders.
Inspire Medical Systems News Summary
Here are the key news stories impacting Inspire Medical Systems this week:
- Positive Sentiment: For Q3 2026, Inspire reported earnings of $0.14 per share and revenue of $206.7 million, topping consensus estimates of $0.09 and $204.3 million, respectively. The earnings beat may have helped support the shares. Article: Q3 earnings and revenues beat estimates
- Neutral Sentiment: The company forecast FY 2026 revenue of $850 million-$860 million, close to the $853.6 million consensus, and EPS of $1.20-$1.40 versus a $1.25 estimate. Analyst targets were mixed: Baird and Piper Sandler raised theirs, while JPMorgan remained neutral and Barclays lowered its target and maintained an underweight rating.
- Negative Sentiment: Despite the quarterly beat, revenue fell 7.9% year over year and EPS declined from $0.38 a year earlier. Management also projected only low-single-digit revenue growth in 2027, a restraint on expectations for a rapid rebound. Article: Inspire projects low-single-digit 2027 revenue growth
About Inspire Medical Systems
Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.
Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.
Read More
- Five stocks we like better than Inspire Medical Systems
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
